Intellia Therapeutics

Intellia advances CRISPR-based in vivo gene editing with lipid nanoparticle delivery for liver and other tissues. Its systemic editing approach contrasts Kernal’s T-cell-specific selective mRNA programming, suiting genetic diseases more than scalable CAR-T.